Vivozon Inc. announced that it expects to receive KRW 49.9999865 billion in funding from Lumimicro Co., Ltd
June 15, 2020
Share
Vivozon Inc. announced a private placement of 2,127,659 common shares at a face value of KRW 500 per share, issued at a price of KRW 23,500 for gross proceeds of KRW 49,999,986,500 on June 16, 2020. The transaction will include participation from Lumimicro Co., Ltd. The company expects to close the transaction on July 1, 2020. The transaction has been approved by the company's board of directors.
Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
VIVOZON PHARMACEUTICAL CO., LTD. 
